NCT00900588已完成2 期
Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescent
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 1
- 主要终点
- HI antibody and Neutralization antibody
研究概览
简要总结
A single center, stratified, randomized and double-blind phase II clinical trial was conducted in adolescents to evaluate the safety and immunogenicity of a split-virion pandemic influenza A vaccine (H5N1).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 12 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adolescent aged 12-17 years old
- •Be able to show legal identity card for the sake of recruitment
- •Volunteers or their parents are able to understand and sign the informed consent
- •Do not participate in other clinical trial
排除标准
- •Any history of allergic reactions
- •Autoimmune disease or immunodeficiency
- •Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids
- •Diabetes mellitus (type I or II), with the exception of gestational diabetes
- •History of thyroidectomy or thyroid disease that required medication within the past 12 months
- •Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years
- •Hypertension that was not well controlled by medication or the blood pressure is more than 145/95 mmHg at enrollment
- •Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
- •Active malignancy or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of study
- •Seizure disorder other than:
- •Febrile seizures under the age of two years old
- •Seizures secondary to alcohol withdrawal more than 3 years ago, or
- •A singular seizure not requiring treatment within the last 3 years
- •Asplenia, functional asplenia or any condition resulting in the absence or removal o the spleen
- •Guillain-Barre Syndrome
- •Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
- •History of any blood products administration within 3 months before the dosing
- •Administration of any other investigational research agents within 30 days before the dosing
- •Administration of any live attenuated vaccine within 30 days before the dosing
- •Administration of subunit or inactivated vaccines, e.g., pneumococcal vaccine, or allergy treatment with antigen injections, within 14 days before the dosing
- •Be receiving anti-TB prophylaxis or therapy currently
- •Axillary temperature > 37.0 centigrade at the time of dosing
- •Psychiatric condition that precludes compliance with the protocol:
- •Past or present psychoses
- •Past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years
- •Disorder requiring lithium
- •Suicidal ideation occurring within five years prior to enrollment
- •Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent
研究组 & 干预措施
10 ug
Experimental
10 microgram split-virion vaccine per dose
干预措施: split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14) (Biological)
15 ug
Experimental
15 microgram split-virion vaccine per dose
干预措施: split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14) (Biological)
30 ug
Experimental
30 microgram split-virion vaccine per dose
干预措施: split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14) (Biological)
5 ug
Active Comparator
5 microgram whole-virion vaccine per dose
干预措施: split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14) (Biological)
结局指标
主要结局
HI antibody and Neutralization antibody
次要结局
- Adverse reactions
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in ChildrenInfluenzaNCT00900991Sinovac Biotech Co., Ltd
已完成
1 期
Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)InfluenzaNCT00424086Alachua Government Services, Inc.1,000
已完成
1 期
Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected AdultsAcquired Immunodeficiency SyndromeImmunologic Deficiency Syndrome, AcquiredSexually Transmitted Diseases, ViralRetroviridae InfectionsHIVNCT04983030Boris Juelg, MD PhD28
已完成
3 期
A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque PsoriasisPlaque PsoriasisNCT04595409Bioeq GmbH392
终止
1 期
Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C VirusChronic Hepatitis CNCT00800007Anza Therapeutics, Inc.5